Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis
Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis
复制标题
DOI：
10.21873/anticanres.15824
复制
发表时间：
2022-07
影响因子：
2
通讯作者：
C. Nakayama;Kiyonori Tanoue;Tetsuya Idichi;H. Shimomura;Y. Kita;Yuto Hozaka;Y. Shinden;Daisuke Matsushita;Akihiro Nakajo;T. Arigami;Yuko Mataki;H. Kurahara;T. Ohtsuka
中科院分区：
文献类型：
--
作者：
C. Nakayama;Kiyonori Tanoue;Tetsuya Idichi;H. Shimomura;Y. Kita;Yuto Hozaka;Y. Shinden;Daisuke Matsushita;Akihiro Nakajo;T. Arigami;Yuko Mataki;H. Kurahara;T. Ohtsuka
背景/目的：肿瘤免疫治疗胰腺癌的发展和应用尚未取得进展，因为其疗效尚未在临床试验中得到证实。在这项研究中，我们旨在探索免疫检查点抑制剂治疗胰腺癌的潜在靶点。材料和方法：我们收集了40例胰腺癌患者的切除标本，这些患者在我们的机构接受了切除术，没有任何术前治疗。我们使用免疫组织化学染色评估程序性死亡受体-1 （PD-1）、T细胞免疫球蛋白粘蛋白-3 (Tim-3)/半凝集素-9和CD155/T细胞免疫受体Ig和ITIM结构域（TIGIT）通路中的分子表达。应用Kaplan-Meier分析评估这些分子的表达模式与患者预后的相关性。结果：胰腺癌组织中CD8+ T细胞数量的增加与患者预后的改善显著相关。此外，PD-1与CD8+ T细胞表达比例较高的患者预后较差。我们观察到Tim-3/Galectin-9和CD155/TIGIT通路与患者预后没有相关性。结论：免疫环境的改变增加了T细胞对肿瘤的浸润，可能导致PD-1通路成为利用免疫检查点抑制治疗胰腺癌的潜在靶点。
Background/Aim: The development and application of cancer immunotherapy to pancreatic cancer has not progressed because its efficacy has not been proven in clinical trials. In this study, we aimed to explore potential targets of immune checkpoint inhibitor therapy for pancreatic cancer treatment. Materials and Methods: We collected resected specimens from 40 patients with pancreatic cancer who underwent resection at our Institution without any preoperative treatment. We evaluated the expression of molecules in the programmed death receptor-1 (PD-1), T cell immunoglobulin mucin-3 (Tim-3)/Galectin-9, and CD155/T cell immunoreceptor with Ig and ITIM domains (TIGIT) pathways using immunohistochemical staining. The correlation between the expression pattern of these molecules and patient prognosis were assessed using Kaplan-Meier analysis. Results: An increased number of CD8+ T cells in pancreatic cancer tissue was significantly associated with a better patient prognosis. Additionally, patients with a higher ratio of PD-1 expression to CD8+ T cells had a worse prognosis. We observed no correlation between the Tim-3/Galectin-9 and CD155/TIGIT pathways and patient prognosis. Conclusion: Modifications in the immune environment to increase T cell infiltration into tumors could result in the PD-1 pathway becoming a potential target to treat pancreatic cancer using immune checkpoint inhibition.